The group's principal activity is to engage in the research and development of proprietary compounds, ent-103 for pain therapy. Ent-103 has the potential to effectively treat a number of medical conditions using various delivery systems. Ent-103 is effective in acute pain states, acute inflammatory pain, neuropathic pain and suppresses the abnormal pain to tactile stimulation that occurs after an incision. At present, the group is pursuing two delivery systems, injectable and topical, for ent-103.
